Medacta Group SA

SWX:MOVE Stock Report

Market Cap: CHF 2.1b

Medacta Group Management

Management criteria checks 3/4

Medacta Group's CEO is Francesco Siccardi, appointed in Nov 2018, has a tenure of 6.17 years. total yearly compensation is €1.86M, comprised of 21.3% salary and 78.7% bonuses, including company stock and options. directly owns 19.88% of the company’s shares, worth CHF422.74M. The average tenure of the management team and the board of directors is 11.5 years and 6 years respectively.

Key information

Francesco Siccardi

Chief executive officer

€1.9m

Total compensation

CEO salary percentage21.3%
CEO tenure6.2yrs
CEO ownership19.9%
Management average tenure11.5yrs
Board average tenure6yrs

Recent management updates

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 01
We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Recent updates

The Price Is Right For Medacta Group SA (VTX:MOVE)

Nov 22
The Price Is Right For Medacta Group SA (VTX:MOVE)

Is Medacta Group (VTX:MOVE) A Risky Investment?

Oct 14
Is Medacta Group (VTX:MOVE) A Risky Investment?

Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

Sep 06
Medacta Group SA (VTX:MOVE) Shares Could Be 32% Above Their Intrinsic Value Estimate

What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Aug 21
What Does Medacta Group SA's (VTX:MOVE) Share Price Indicate?

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Aug 06
Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

Jun 20
Medacta Group SA's (VTX:MOVE) P/E Still Appears To Be Reasonable

We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

May 01
We Discuss Why Medacta Group SA's (VTX:MOVE) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Apr 17
Medacta Group (VTX:MOVE) Has A Pretty Healthy Balance Sheet

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Mar 29
Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Feb 22
Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Feb 07
Medacta Group (VTX:MOVE) Will Be Hoping To Turn Its Returns On Capital Around

Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Dec 18
Getting In Cheap On Medacta Group SA (VTX:MOVE) Might Be Difficult

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Dec 04
Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Nov 15
Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

Oct 30
Returns On Capital Signal Tricky Times Ahead For Medacta Group (VTX:MOVE)

If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Oct 17
If EPS Growth Is Important To You, Medacta Group (VTX:MOVE) Presents An Opportunity

Is Medacta Group (VTX:MOVE) Using Too Much Debt?

Sep 29
Is Medacta Group (VTX:MOVE) Using Too Much Debt?

Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Aug 11
Calculating The Intrinsic Value Of Medacta Group SA (VTX:MOVE)

Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Jul 27
Is Now The Time To Look At Buying Medacta Group SA (VTX:MOVE)?

Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

Jul 03
Be Wary Of Medacta Group (VTX:MOVE) And Its Returns On Capital

At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Apr 28
At CHF117, Is It Time To Put Medacta Group SA (VTX:MOVE) On Your Watch List?

Is Medacta Group (VTX:MOVE) A Risky Investment?

Apr 08
Is Medacta Group (VTX:MOVE) A Risky Investment?

Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Dec 25
Is Now An Opportune Moment To Examine Medacta Group SA (VTX:MOVE)?

Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Dec 09
Capital Allocation Trends At Medacta Group (VTX:MOVE) Aren't Ideal

Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Nov 09
Does Medacta Group (VTX:MOVE) Have A Healthy Balance Sheet?

Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

Sep 16
Why Medacta Group SA (VTX:MOVE) Could Be Worth Watching

The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Aug 20
The Returns On Capital At Medacta Group (VTX:MOVE) Don't Inspire Confidence

Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Jul 02
Here's Why Medacta Group (VTX:MOVE) Has Caught The Eye Of Investors

Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

May 28
Should You Think About Buying Medacta Group SA (VTX:MOVE) Now?

Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

May 12
Medacta Group (VTX:MOVE) Is Reinvesting At Lower Rates Of Return

These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Mar 31
These 4 Measures Indicate That Medacta Group (VTX:MOVE) Is Using Debt Reasonably Well

Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Mar 17
Does Medacta Group (VTX:MOVE) Deserve A Spot On Your Watchlist?

Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Feb 07
Capital Investments At Medacta Group (VTX:MOVE) Point To A Promising Future

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Dec 10
Should You Investigate Medacta Group SA (VTX:MOVE) At CHF133?

Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Nov 05
Medacta Group (VTX:MOVE) Knows How To Allocate Capital

Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Sep 30
Here's Why Medacta Group (VTX:MOVE) Can Manage Its Debt Responsibly

Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Aug 26
Is It Too Late To Consider Buying Medacta Group SA (VTX:MOVE)?

Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Jul 20
Medacta Group (VTX:MOVE) May Have Issues Allocating Its Capital

Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

May 19
Should You Investigate Medacta Group SA (VTX:MOVE) At CHF119?

We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

Apr 05
We Think Medacta Group (VTX:MOVE) Can Stay On Top Of Its Debt

What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Mar 02
What You Need To Know About Medacta Group SA's (VTX:MOVE) Investor Composition

Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?

Feb 02
Is Medacta Group SA's (VTX:MOVE) 7.6% ROE Better Than Average?

The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More

Jan 12
The Medacta Group (VTX:MOVE) Share Price Has Gained 24% And Shareholders Are Hoping For More

Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture

Dec 21
Returns On Capital At Medacta Group (VTX:MOVE) Paint An Interesting Picture

Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?

Dec 03
Should You Use Medacta Group's (VTX:MOVE) Statutory Earnings To Analyse It?

CEO Compensation Analysis

How has Francesco Siccardi's remuneration changed compared to Medacta Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

€56m

Mar 31 2024n/an/a

€52m

Dec 31 2023€2m€396k

€47m

Sep 30 2023n/an/a

€49m

Jun 30 2023n/an/a

€50m

Mar 31 2023n/an/a

€48m

Dec 31 2022€2m€372k

€46m

Sep 30 2022n/an/a

€47m

Jun 30 2022n/an/a

€47m

Mar 31 2022n/an/a

€49m

Dec 31 2021€2m€354k

€52m

Sep 30 2021n/an/a

€54m

Jun 30 2021n/an/a

€57m

Mar 31 2021n/an/a

€47m

Dec 31 2020€1m€339k

€37m

Sep 30 2020n/an/a

€24m

Jun 30 2020n/an/a

€10m

Mar 31 2020n/an/a

€11m

Dec 31 2019€843k€247k

€12m

Compensation vs Market: Francesco's total compensation ($USD1.91M) is above average for companies of similar size in the Swiss market ($USD1.32M).

Compensation vs Earnings: Francesco's compensation has been consistent with company performance over the past year.

CEO

Francesco Siccardi (47 yo)

6.2yrs

Tenure

€1,861,824

Compensation

Dr. Francesco Siccardi has been Chief Executive Officer of Medacta Group SA since November 1, 2018. He is a Member of the Board of Directors of Surgical Practice Resource Group SA, Lugano since 2015 and of...

Leadership Team

NamePositionTenureCompensationOwnership
Alberto Siccardi
Founder & Non Executive Chairman7yrs€352.21k10.18%
CHF 216.6m
Francesco Siccardi
Chief Executive Officer6.2yrs€1.86m19.88%
CHF 422.7m
Corrado Farsetta
Chief Financial Officer14yrsno datano data
Gianluca Olgiati
Senior Director of Global Marketingno datano datano data
Asif Hussain
Chief People Officerno datano datano data
Alessandro Siccardi
Chief Supply Chain Officer9yrsno data19.78%
CHF 420.7m
Filippo Cappelli
Head of ITno datano datano data
Giovanni Galli
Chief Commercial Officerno datano datano data
Massimiliano Bernardoni
Chief Innovation Officerno datano datano data
Donato Cortesi
Secretary of the Boardno datano datano data
Antonio Di Brino
Group Vice President of Finance & Taxno datano datano data

11.5yrs

Average Tenure

51.5yo

Average Age

Experienced Management: MOVE's management team is seasoned and experienced (11.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alberto Siccardi
Founder & Non Executive Chairman7yrs€352.21k10.18%
CHF 216.6m
Victor Balli
Lead Independent Director6yrs€231.19k0.013%
CHF 266.5k
Riccardo Braglia
Independent Director4.1yrs€128.89k0.16%
CHF 3.5m
Philippe Weber
Independent Director5.8yrs€152.33kno data
Maria Siccardi Tonolli
Non-executive Director7yrs€137.62k19.78%
CHF 420.7m

6.0yrs

Average Tenure

64yo

Average Age

Experienced Board: MOVE's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 06:50
End of Day Share Price 2024/12/30 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Medacta Group SA is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Samuel EnglandBerenberg
Christoph GretlerCredit Suisse
David AdlingtonJ.P. Morgan